忍者ブログ
ウイルスの力で病気を治す
[14] [13] [12] [11] [10] [9] [8] [7] [6] [5] [4]
×

[PR]上記の広告は3ヶ月以上新規記事投稿のないブログに表示されています。新しい記事を書く事で広告が消えます。

Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial


SAN DIEGO, Sept. 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's licensee, sanofi-aventis, has confirmed the completion of enrollment in a multinational 500-patient pivotal Phase 3 clinical trial of its angiogenesis therapy based on Vical's non-viral DNA delivery technology. Sanofi-aventis expects final data from this trial in late 2010.

"We are pleased that sanofi-aventis, one of our two partners in the angiogenesis field, has advanced according to plan with the Phase 3 testing of this novel therapy," said Vijay B. Samant, Vical's President and Chief Executive Officer, "and we would expect timely trial completion. Angiogenesis is among the most promising near-term human applications of our DNA delivery technology, and represents a substantial potential market for which there is no adequate therapy. The ability of plasmid DNA to induce production of angiogenesis protein locally at the site of injection ideally matches the desired treatment profile for peripheral vascular disease."

PR

コメント


コメントフォーム
お名前
タイトル
文字色
メールアドレス
URL
コメント
パスワード
  Vodafone絵文字 i-mode絵文字 Ezweb絵文字


トラックバック
この記事にトラックバックする:


忍者ブログ [PR]
カレンダー
10 2017/11 12
S M T W T F S
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30
リンク
フリーエリア
最新CM
[08/27 ふぁみれど]
[08/27 ふぁみれど]
[05/11 ふぁみれど]
[04/13 ふぁみれど]
[01/23 シドレミファ]
最新TB
プロフィール
HN:
No Name Ninja
性別:
非公開
バーコード
ブログ内検索
P R
カウンター
忍者アド
忍者アド
アクセス解析
忍者アナライズ
アクセス解析